A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2022-11-13
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared
to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).